Original White Feather Rice Intranet
Highlights
A few days ago, the official website of CDE showed that Sinopharm Yixin Pharmaceutical's levocarnitine injection was under review as a generic Class 4 production. According to data from Minenet, the terminal sales of levocarnitine injection in China's public medical institutions will exceed 1.2 billion yuan in 2023. At present, Sinopharm Yixin Pharmaceutical has 4 products under review, of which 3 are anti-tumor drugs.
Levocarnitine injection is suitable for a series of complications caused by secondary carnitine deficiency in patients with chronic renal failure and long-term hemodialysis, such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, hypotension and muscle spasm during dialysis.
Sales of terminal levocarnitine injection in China's public medical institutions in recent years (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
In 2023, the terminal sales scale of levocarnitine injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions) will exceed 1.2 billion yuan, and it is the top 15 products for digestive system and metabolic drug injections, and the market share of Alpha Sigma, Northeast Pharmaceutical, Shenyang First Pharmaceutical, and Changzhou Lanling Pharmaceutical ranks among the top three.
According to the data of Minenet, 19 companies have production approvals for levocarnitine injection, and 13 companies such as Northeast Pharmaceutical, Shenyang First Pharmaceutical, Shandong Qidu Pharmaceutical, and Yunnan Longhai Natural Plant Pharmaceutical have been evaluated. The supplementary application for consistency evaluation of Hainan LansmithKline Pharmaceutical is under review, and 9 companies, including Sinopharm Yixin Pharmaceutical, Zhejiang Prokangyu Pharmaceutical, and Hainan Zhuoke Pharmaceutical, are under review with generic 4 types of production reports, and they will be deemed to have passed the evaluation after approval.
Sinopharm Yixin Pharmaceutical reported the production of products under review
Source: Minenet China Declaration Progress (MED) database
At present, Sinopharm Yixin Pharmaceutical has 4 products under review, among which calcium folinate injection, trifluridine tipiracil tablets, and methotrexate tablets are all antineoplastic drugs.
The company focuses on the field of anti-tumor and is committed to building a high-end manufacturing enterprise with "anti-tumor products based on therapeutic drugs and supplemented by peripheral products", the main products include mannan peptide for injection, thymus pentapeptide for injection, cytarabine hydrochloride for injection, octreotide acetate injection, etc.
Source: CDE official website, Minenet database
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated based on the average retail price of the product at the terminal. If there is any omission, please correct it.